Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A personalised cancer vaccine keeps patients disease-free. Transgene's TG4050, an AI-powered individualised vaccine for high-risk head and neck cancer, kept all 16 treated patients relapse-free in a Phase 1 trial, compared to three relapses in the control group. The promising results sent Transgene's stock soaring 20%, though researchers caution the small sample size limits statistical significance.
French biotech Transgene reported encouraging Phase 1 results for TG4050, its AI-powered personalised cancer vaccine developed with Japan's NEC Corp, targeting patients with high-risk head and neck cancer following surgery and chemoradiotherapy. The vaccine uses NEC's artificial intelligence to identify patient-specific tumour targets, making each dose uniquely tailored to the individual.
The trial results turned heads: all 16 patients who received TG4050 remained disease-free, while three out of 16 patients in the control arm experienced relapses. Analysts called the longer follow-up data a "robust dataset," though the study's authors were quick to note that the small patient numbers make it impossible to establish statistical significance just yet.
By the Numbers:
Why it matters: Personalised cancer vaccines are one of oncology's hottest frontiers — Moderna's melanoma vaccine already showed a reduction in recurrence risk. TG4050's early results add momentum to the field, with larger trials needed to confirm whether this tailored approach could become a standard post-treatment option for head and neck cancer patients.
